Summary & Overview
HCPCS Q4131: Epifix or Epicord, Biologic Wound Graft per cm2
HCPCS Level II code Q4131 denotes Epifix or Epicord, a human amniotic membrane biologic graft billed per square centimeter for use in advanced wound care and tissue regeneration. This code matters nationally as adoption of biologic grafts grows across outpatient wound centers, hospital outpatient departments, and ambulatory surgery centers — impacting clinical workflows, supply costs, and payer coverage policies. Coverage and payment for such biologic products influence access to advanced wound therapies and downstream outcomes for chronic wounds and complex soft-tissue injuries.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of Q4131, typical sites of service, and the national relevance of billing for human amniotic membrane grafts. The publication summarizes benchmark considerations for utilization and payment, highlights policy developments affecting biologic graft coverage, and provides clinical context on indications and service delivery. Data not available in the input will be noted where applicable. This piece is intended to inform revenue cycle leaders, clinical managers, and policy analysts about the implications of billing and coverage for HCPCS Level II code Q4131 at a national level.
Billing Code Overview
HCPCS Level II code Q4131 represents Epifix or Epicord, billed per square centimeter. This code covers biologic graft material derived from human amniotic membrane used to support wound healing and tissue regeneration.
-
Service type: Application of biologic wound graft
-
Typical site of service: Outpatient wound care settings, hospital outpatient departments, ambulatory surgical centers, and specialty clinics providing advanced wound management
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic, non-healing lower extremity wound (such as a diabetic foot ulcer or venous stasis ulcer) that has failed standard wound care including debridement, offloading, infection control, and moist wound dressings. The clinician evaluates the wound at an outpatient wound care clinic or hospital-based clinic. After assessment including wound measurements, infection status, vascular status, and documentation of prior conservative therapies, the provider determines that an advanced biologic graft is indicated.
The clinical workflow includes wound bed preparation (sharp or surgical debridement) and hemostasis, application of the dehydrated human amnion/chorion membrane product billed as Q4131 (Epifix or Epicord) sized and priced per square centimeter, securing the graft to the wound bed, and covering with an appropriate dressing. Post-procedure instructions address offloading, wound care follow-up, and signs of infection. Typical sites of service are outpatient wound care centers, hospital outpatient departments, ambulatory surgery centers (if debridement or more complex procedures are performed), and occasionally inpatient settings for patients with comorbid conditions requiring admission.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, Separately Identifiable Evaluation and Management Service on the Same Day |